Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 9060 results

  1. Budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

  2. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

  3. Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

    Awaiting development Reference number: GID-TA12464 Expected publication date: TBC

  4. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

  5. Diabetic foot problems: prevention and management - topical wound oxygen therapy for diabetic foot ulcers

    Awaiting development Reference number: GID-NG10552 Expected publication date: TBC

  6. Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date: TBC

  7. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  27 July 2027

  8. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

  9. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  06 August 2026

  10. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date:  03 September 2026

  11. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

  12. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

  13. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  04 February 2027

  14. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

  15. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC